P2RY1 and P2RY12 polymorphisms and on-aspirin platelet reactivity in patients with coronary artery disease

被引:36
作者
Timur, A. A. [1 ]
Murugesan, G. [1 ]
Zhang, L.
Aung, P. P. [1 ]
Barnard, J.
Wang, Q. K. [2 ,3 ]
Gaussem, P. [4 ]
Silverstein, R. L. [5 ]
Bhatt, D. L. [6 ,7 ]
Kottke-Marchant, K. [1 ]
机构
[1] Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44195 USA
[2] Cleveland Clin, Lerner Res Inst, Dept Mol Cardiol, Cleveland, OH 44195 USA
[3] Cleveland Clin, Lerner Res Inst, Ctr Cardiovasc Genet, Cleveland, OH 44195 USA
[4] Univ Paris 05, Hop Europe Georges Pompidou, AP HP, INSERM,U765, Paris, France
[5] Cleveland Clin, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA
[6] Harvard Univ, Sch Med, Boston, MA USA
[7] Brigham & Womens Hosp, VA Boston Healthcare Syst, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
Coronary artery disease; aspirin; platelet reactivity; P2RY1 and P2RY12 receptors; SNP; ANTIPLATELET THERAPY; RECEPTOR GENE; RESISTANCE; IDENTIFICATION; INTERVENTION; CLOPIDOGREL; PREVALENCE; ADP;
D O I
10.1111/j.1751-553X.2012.01420.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Association of P2RY1 and P2RY12 polymorphisms with on-aspirin platelet reactivity was investigated. Materials and methods: Platelet reactivity was assessed by the light transmission aggregometry and TxB2 assay in 423 patients with coronary artery disease (CAD) on aspirin. High residual platelet reactivity (RPR) was defined by =20% and =70% maximal aggregation stimulated with 0.5 mg/mL arachidonic acid (AA) and 10 mu m ADP, respectively. Moderate RPR was considered aggregation =20% with AA, =70% with ADP, or =1 ng/mL stimulated TxB2. Fourteen P2RY1 and 35 P2RY12 single nucleotide polymorphisms (SNPs) were genotyped. Results: High RPR was detected in 24% of the patients. Moderate RPR was observed in 31% with AA, 57% with 5 mu m ADP, and 82% with 10 mu m ADP. Stimulated TxB2 was =1 ng/mL in 23% of patients. P2RY12 SNP rs9859538 was associated with high RPR (OR = 2.16, 95% CI = 1.243.75, P-value = 0.004). Four P2RY12 SNPs, rs1491974, rs10513398, rs3732765, and rs10935841, showed association with moderate RPR (OR = 1.792.94, P-value = 0.040.028), while five, rs7615865, rs1388623, rs1388622, rs7634096, and rs7637803, were associated with low RPR (OR = 0.500.55, P-value = 0.0080.026), following ADP stimulation. TxB2 level <1 ng/mL was linked to five P2RY1 SNPs, rs1439010, rs1371097, rs701265, rs12497578, and rs2312265 (OR = 0.360.54, P-value = 0.0030.039). Conclusions: Polymorphisms in P2RY1 and P2RY12 are associated with on-aspirin platelet reactivity in patients with CAD.
引用
收藏
页码:473 / 483
页数:11
相关论文
共 50 条
  • [1] P2RY12 Gene Polymorphisms and Effect of Clopidogrel on Platelet Aggregation
    Galic, Edvard
    Vrbanic, Luka
    Kapitanovic, Sanja
    Ivkovic, Tina Catela
    Petro, Dubravka
    Vukovic, Ivica
    Bsharat, Rebhi Sari
    Milicevic, Zvonko
    Vcev, Aleksandar
    Mirat, Jure
    COLLEGIUM ANTROPOLOGICUM, 2013, 37 (02) : 491 - 498
  • [2] Nonsynonymous single nucleotide polymorphisms in candidate genes P2RY1, P2RY12 and CYP2C19 for clopidogrel efficacy in cats
    Ueda, Yu
    Li, Ronald Hak Long
    Tablin, Fern
    Ontiveros, Eric S.
    Stern, Joshua A.
    ANIMAL GENETICS, 2018, 49 (04) : 356 - 357
  • [3] Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3
    Storey, Robert F.
    Thornton, S. Melissa
    Lawrance, Rachael
    Husted, Steen
    Wickens, Mark
    Emanuelsson, Hakan
    Cannon, Christopher P.
    Heptinstall, Stan
    Armstrong, Martin
    PLATELETS, 2009, 20 (05) : 341 - 348
  • [4] Predictors of high on-aspirin platelet reactivity in elderly patients with coronary artery disease
    Zhang, J. W.
    Liu, W. W.
    McCaffrey, Timothy A.
    He, X. Q.
    Liang, W. Y.
    Chen, X. H.
    Feng, X. R.
    Fu, Sidney W.
    Liu, M. L.
    CLINICAL INTERVENTIONS IN AGING, 2017, 12 : 1271 - 1279
  • [5] Haplotype of platelet receptor P2RY12 gene is associated with residual clopidogrel on-treatment platelet reactivity
    Nie, Xiao-yan
    Li, Jun-lei
    Zhang, Yong
    Xu, Yang
    Yang, Xue-li
    Fu, Yu
    Liang, Guang-kai
    Lu, Yun
    Liu, Jian
    Shi, Lu-wen
    JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2017, 18 (01): : 37 - 47
  • [6] Association between P2RY12 gene polymorphisms and adverse clinical events in coronary artery disease patients treated with clopidogrel: A systematic review and meta-analysis
    Li, Jun-lei
    Fu, Yu
    Qin, Si-bei
    Liang, Guang-kai
    Liu, Jian
    Nie, Xiao-yan
    Chen, Jing
    Shi, Lu-wen
    Shao, Hong
    Lu, Yun
    GENE, 2018, 657 : 69 - 80
  • [7] Polymorphisms of Platelet ADP Receptor P2RY12 in the Risk of Venous Thromboembolism in the Korean Population
    Jang, Moon Ju
    Jeon, Young Joo
    Min, Kyung Tae
    Oh, Jisu
    Chong, So Young
    Park, Seonyang
    Yun-Choi, Hye Sook
    Oh, Doyeun
    Nam Keun Kim
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2012, 18 (04) : 416 - 420
  • [8] Common Variation in the Platelet Receptor P2RY12 Gene Is Associated With Residual On-Clopidogrel Platelet Reactivity in Patients Undergoing Elective Percutaneous Coronary Interventions
    Rudez, Goran
    Bouman, Heleen J.
    van Werkum, Jochem W.
    Leebeek, Frank W. G.
    Kruit, Adrian
    Ruven, Hendrik J. T.
    ten Berg, Jurrien M.
    de Maat, Moniek P. M.
    Hackeng, Christian M.
    CIRCULATION-CARDIOVASCULAR GENETICS, 2009, 2 (05) : 515 - U216
  • [9] Markers of endothelial and platelet activation are associated with high on-aspirin platelet reactivity in patients with stable coronary artery disease
    Pettersen, Alf-Age R.
    Arnesen, Harald
    Opstad, Trine B.
    Bratseth, Vibeke
    Seljeflot, Ingebjorg
    THROMBOSIS RESEARCH, 2012, 130 (03) : 424 - 428
  • [10] The Association between Multi-Vessel Coronary Artery Disease and High On-Aspirin Platelet Reactivity
    Shiyovich, Arthur
    Sasson, Liat
    Lev, Eli
    Solodky, Alejandro
    Kornowski, Ran
    Perl, Leor
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (03) : 449 - 454